In order to develop an integrated pharmacokinetic/viral dynamic (PK/VD) model to predict long-term virological response rates to daclatasvir (DCV) and asunaprevir (ASV) combination therapy in patients infected with genotype 1 (GT1) chronic hepatitis C virus (HCV), a systematic publication search was conducted for DCV and ASV administered alone and/or in combination in healthy subjects or patients with GT1 HCV infection. On the basis of a constructed meta-database, an integrated PK/VD model was developed, which adequately described both DCV and ASV PK profiles and viral load time curves. The IC 50 values of DCV and ASV were estimated to be 0.041 and 2.45 μg/L, respectively, in GT1A patients. A sigmoid E max function was applied to describe the antiviral effects of DCV and ASV, depending on the drug concentrations in the effect compartment. An empirical exponential function revealed that IC 50 changing over time described drug resistance in HCV GT1A patients during DCV or ASV monotherapy. Finally, the PK/VD model was evaluated externally by comparing the expected and observed virological response rates during and post-treatment with DCV and ASV combination therapy in HCV GT1B patients. Both the rates were in general agreement. Our PK/VD model provides a useful platform for the characterization of pharmacokinetic/pharmacodynamic relationships and the prediction of long-term virological response rates to aid future development of direct acting antiviral drugs.
Introduction
More than 185 million people globally have been estimated to be chronically infected with the hepatitis C virus (HCV), which is one of the leading causes of cirrhosis and liver failure [1] . For the past two decades, until 2011, PEGylated interferon-α (Peg-IFN-α) in combination with ribavirin (RBV) was recommended as a standard-of-care (SOC) treatment for chronic hepatitis C [2] . However, fewer than 50% of patients infected with HCV genotype 1 (GT1, the most prevalent and difficult-to-cure genotype in the western world) treated with SOC achieve successful HCV treatment outcomes, ie, sustained virological response (SVR) [3] [4] [5] . Recently, novel directacting antiviral agents (DAAs) have been developed to target specific nonstructural proteins in the HCV life cycle, including NS3/4A protease inhibitors, NS5A protein inhibitors, and NS5B polymerase inhibitors [6] . The current approved IFNbased regimen and Peg-IFN-and RBV-free (PR-free) regimen show high potency, favorable tolerability profile, a higher barrier to resistance, shorter treatment duration, all-oral regimen, pan-genotypic character, fewer drug interactions and a decreased pill burden, as compared with the previous standard treatment [7] . A combination of DAA therapy, which has a good safety profile and does not include IFN or RBV that lack cross-resistance, will probably be the new recommended regimen and may possibly eradicate HCV worldwide in the near future [7] . Asunaprevir (BMS650032, ASV) is a selective NS3 protease inhibitor that is rapidly absorbed over time and subse-quently reaches a maximum plasma concentration (t max ) of 2-4 h and is eliminated primarily via cytochrome P450 (CYP) 3A4-mediated hepatic oxidative metabolism and fecal excretion, with an elimination half-life (t 1/2 ) of 15-20 h [8] . Daclatasvir (BMS790052, DCV) is a first-in-class, highly selective NS5A replication complex inhibitor, which is rapidly absorbed with a t max of 1-2 h and is mainly metabolized by hepatic CYP3A4 and excreted in fecal matter, with an elimination t 1/2 of 13-15 h [9, 10] . A drug-drug interaction (DDI) study in healthy subjects has suggested that coadministration of ASV and DCV does not result in a clinically meaningful pharmacokinetic (PK) interaction. ASV has shown activity against HCV GT1 and 4 in combination with Peg-IFN/RBV, or as part of alloral DAA combinations in current ongoing Phase III clinical trials [11] [12] [13] . DCV was initially approved in Europe, Japan and Brazil for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of HCV infection in adults. In July 2014, the DCV+ASV dual regimen was approved as the first all-oral, PR-free anti-HCV regimen for previously null responders to PR-treatment in Japan. In a recent global Phase III study, this all-oral dual therapy has been found to provide high rates of SVR in treatment-naïve (90%), non-responder (82%), and ineligible, intolerant, or ineligible and intolerant (82%) patients with GT1B infection [14] . Modeling of PK/viral dynamics (VD) has helped to elucidate the dynamic parameters governing infection, reproduction and death of virions, production and death of infected and healthy hepatocytes, as well as the antiviral effects of DAAs [15] , and to investigate the possible interaction between the combined drugs [16] . HCV dynamic models have provided a means to compare outcomes in varied treatment regimens and in different patient populations [15, 17] . Although many HCV dynamic models have been established for IFN or/and RBV treatment [18] [19] [20] , DAA monotherapy [21] [22] [23] [24] and combination therapy using PR and DAA agents [25, 26] , few studies have explored and predicted the combined efficacy of DAA agents by using a PK/VD modeling approach.
In this article, we developed an integrated PK/VD model to examine the dynamics of HCV infection under DCV monotherapy and ASV monotherapy; we also used the model to predict long-term virological response rates during and posttreatment of DCV and ASV combination therapy in patients with GT1 HCV infection.
Materials and methods
Literature search and database construction A systematic search of available information published in English in or before February 2017 was performed in PubMed, Google Scholar and the websites of National AIDS Treatment Advocacy Project (NATAP) [27] and ClinicalTrials.gov by using "BMS650032", "asunaprevir", "BMS790052" and "daclatasvir" as keywords. Clinical studies on the PK or efficacy of DCV or ASV treatment alone, as well as these two drugs used in combination, in healthy subjects or HCV patients were included in this analysis. Additional trials were identified by crossreferencing articles.
Two independent reviewers (He-chuan WANG & Yue QIU.) constructed the dataset manually by collecting information in text or tables and extracting data from graphics, by using GetData Graph Digitizer (Version 2.24). In cases of disagreement, consensus was reached between the reviewers via discussion. The database was cross-checked by a third reviewer (Liang LI). The initial dataset consisted of viral load data, presented either as a change from the baseline and/or the actual viral load measurements, depending on the information provided in the publication. For the purpose of model analysis, the change from the baseline data was converted to actual viral load measurements for all records by adding the mean baseline value of the corresponding treatment arm.
PK/VD modeling A sequential PK/VD model was developed by using a nonlinear mixed-effects modeling approach. The PK models were built separately for DCV and ASV, and this was followed by a VD model describing the interaction between the virus and the target cells, as depicted in Figure 1 .
Software
Population analysis was performed by using a first-order conditional estimation with interaction (FOCEI) method in NON-MEM (Version 7.3.0) with PsN (Version 4.2.0) and a gFOR-TRAN compiler (Version 4.8.2). The complete modeling process was conducted in the interface software Pirana (Version 2.8.2). Graphical data visualization, evaluation of NONMEM outputs, construction of goodness-of-fit plots and graphical model comparisons were conducted using R (Version 2.15.0).
PK models
Given the availability of only study-level aggregate PK data in our meta-database, a population-based meta-analysis approach was used to develop PK models for DCV and ASV separately. A disposition model for the drug was determined by testing a one-, two-, and three-compartment model with linear clearance. Zero-order, first-order, Michaelis-Menten saturable, and simultaneous zero-and first-order absorption processes were investigated to capture the absorption phase. Structural model selection was based on Akaike Information Criterion (AIC) and goodness-of-fit plots. A log-normal random effect model (Equation 1) was chosen to describe the inter-arm variability (IAV) for all parameters. The additive residual error (Equation 2) was weighed by the sample size (n mk ) of arm m for drug k:
where θ mk is the estimated parameter value of arm m for drug k, θ k is the typical value of the population parameter and η θmk is specific IAV of parameter θ k . Y mjk is the j th natural logtransformed observation in arm m for drug k, F mjk is the model prediction, and ε mjk is the residual error.
VD model
The VD model ( Figure 1 ) was developed on the basis of the work of Neumann et al [28] to describe the biphasic decline of HCV RNA after DCV monotherapy or ASV monotherapy treatment of HCV. The model included three variables (Equations 3-5): uninfected target cells (T), productively infected cells (I), and free virus (V). Viral infection was assumed to occur at a rate proportional to the product of the densities of virus and target cells, β·V·T (the law of mass action). Infected cells were lost by either natural death or immune attack at a rate of δ·I. Virus was released from productively infected cells at a rate of p·I and cleared at a rate of c·V. DCV or ASV was assumed to inhibit viral production with efficacy E ijk .
The viral dynamics was assumed to be at steady state prior to the initiation of therapy; therefore the initial values of the viral load (Equation 6), target cells (Equation 7) and infected cells (Equation 8) can be derived from Equations 3-5:
It was also assumed that DCV and ASV shared the same systemic parameters in the VD model. This assumption was tested by allowing for different parameter estimates for the two drugs. The maximum number of hepatocytes (T MAX ), death rate of target cells d, infected cell production rate β and virion production rate p were fixed to values from the literature [15] . The VD model was linked to the PK models via an effect compartment (Equation 9) to account for the possible time delay observed between plasma drug concentrations and antiviral activity, which corresponded with previously reported results [29] . Because only aggregate PK data were available in our analysis, the population drug concentrations in the specific arm m (C mjk ) predicted from PK models were assumed to distribute to the individual effect compartment C e,ijk ; k e,k is the rate constant governing the disposition of the drug k from the central compartment to effect compartment.
The inhibitory effect of production of virions E ijk can be described by using a sigmoid E max function expressed by the concentration at the effect compartment C e,ijk assuming a maximum inhibition of 100%
where IC 50,ijk is the j th concentration of the i th subject in the effect compartment, which results in 50% inhibition of the virus production for the drug k, and γ ik is the shape factor. To capture the rebound of viral load observed in the MAD studies, which was due to the rapid emergence of viral resistance [30] , an empirical exponential function with a coefficient of K r,ik revealing IC 50,ijk was used. The value changed over time during therapy in the model: A i depot compartment of drug k (k represents DCV or ASV, the same hereinafter); X k central compartment; P k peripheral compartment; C e,k drug concentration in effect compartment; Q k inter-compartment clearance; K a,k first-order absorption rate constant; K ce,k elimination rate constant from central compartment to effect compartment; K e0,k elimination rate constant of effect compartment; CL k elimination clearance from central compartment; D ASV duration of zeroorder absorption for ASV; FK fraction of ASV dose absorbed by the firstorder mechanism; the inhibition efficacy of viral replication E is driven by the drug concentration in effect compartment.
Inter-individual variability (IIV) of parameters in the VD model was assumed to have a log-normal distribution. The viral load data (V obs,ijk ) and model predictions (V pred,ijk ) were log 10 -transformed for the modeling analysis, and their residual variability (ε ijk ) was modeled by using an additive error model, as shown in Equation 12.
log 10 V obs,ijk = log 10 V pred,ijk + ε ijk (12) Covariate model Potential covariates were tested for statistical significance for both the PK and VD models by using the stepwise forward addition method, and this was followed by a stepwise backward elimination procedure. OFV changes of 3.84 (χ 2 , df=1, α =0.05) or 7.88 (χ 2 , df=1, α=0.005) were used as a cutoff criterion for the inclusion and exclusion of the covariate, respectively. An improvement in the precision of the parameter estimate (relative standard error), and decrease in inter-arm or interindividual and residual variability were also used to determine the importance of the covariate as a predictor.
Model evaluation and validation
A goodness-of-fit plot was assessed to reveal the model capacity for describing aggregate PK data or individual viral load data. The predictive capacity of the model was also tested by performing 500 simulations based on the parameter estimates to predict the observed virological response rates during and after combination therapy with DCV and ASV in the external validation study. In each simulation, 100 virtual subjects were generated for each of three combination dosing regimens: 1) DCV 60 mg QD+ASV 600 mg BID for 24 weeks in patients with GT1A HCV; 2) DCV 60 mg QD+ASV 200 mg QD for 24 weeks in patients with GT1B HCV and 3) DCV 60 mg QD+ ASV 200 mg BID for 24 weeks in patients with GT1B HCV. The combined antiviral efficacy E COMB,ij of DCV and ASV was assumed to take an additive form:
In the simulation, cure or complete virion eradication was determined from the viral dynamics via implementation of a viral eradication boundary. At the timepoint at which treatment drives the system to less than one infected hepatocyte, the production of virions was set to zero. Simulated response rates were calculated as the proportion of patients whose HCV RNA measurements were below the predefined lower limit of detection (LLOD) of 10 IU/mL. Parameter uncertainty was not considered in the simulations.
Results
Included studies A total of 26 clinical trials, representing 72 treatment arms with 362 healthy subjects and 1368 HCV-infected patients, as presented in Table 1 , were included in this analysis. Of these, 18 trials provided aggregate concentration data for PK models, four trials provided individual viral load data for VD models and 7 trials provided virological response information for model evaluation. Eight trials reported DCV and ASV treated in combination, whereas results for DCV and ASV treated alone were available for 7 and 11 trials, respectively. Table 2 shows a summary of the available baseline demographic information for each study. In those 4 studies for VD modeling analysis, 82.6% of 72 HCV infected patients were treatmentnaïve for PR. Only patients infected with GT1 HCV were included in these trials, and 77% of them had HCV GT1A, whereas others had GT1B. The median baseline viral load was 6.76×10
6 IU/mL.
PK model
A total of 465 aggregate DCV plasma concentrations from 198 subjects in 30 unique arms of 7 clinical trials and a total of 602 ASV aggregate concentrations from 290 subjects in 35 treatment arms of 11 clinical trials were used for PK modeling analyses. The dispositions of DCV and ASV were each well described by a two-compartment distribution model with linear elimination. The DCV absorption phase was best captured by a first-order absorption model. The SAD study in healthy subjects indicated that ASV exposure increased when it was administered as a solution (vs suspension) or with a high-fat meal, and the effect was greater for C max than AUC. This result suggested a saturable first-pass process, although the mechanism remains to be defined. The simultaneous zero-and firstorder absorption model best described the absorption phase for ASV. The population PK parameter estimates are summarized in Table 3 . All PK parameters were estimated with reasonable precision, with relative standard errors less than 30%.
The goodness-of-fit plots ( Figure 2 ) showed good agreement between the arm-level predictions and the observed plasma concentrations for both DCV and ASV. Figure 3 shows that the estimated DCV and ASV PK time profiles adequately captured the observed concentrations after single dose and multiple dose administration in healthy subjects or in HCV-infected patients.
PK/VD model A total of 952 viral load measurements from 72 patients with GT1A or GT1B HCV infection receiving DCV or ASV in 2 single-and 2 multiple-ascending dose studies were pooled together to perform population VD modeling analysis. The estimated PK parameters were utilized to drive the pharmacodynamic modeling. A summary of population pharmacodynamic parameters obtained from the final VD model is listed in Table 4 . Owing to the complexity of the model, the available viral load data did not contain sufficient information to estimate all parameters precisely. Therefore, most VD system parameters were fixed to the values from the literature [15] , except for virion clearance rate constant c and virion production rate constant p, which were estimated to be 20.4 per day and 148 virions/ cells/day, with relative standard errors of 22.1% and 141.1%, respectively. The inclusion of an effect compartment for both DCV and ASV in this model resulted in a significant decrease [36] OL, SD, ADME Cohort [44] AI447017 [45] [46] [47] RD, OL, Phase 2a in the objective function value (ΔOFV=-92.3, df=2). The rate constants determining the equilibration process between the plasma and effect site were 0.0041 per day and 1.19 per day for DCV and ASV, respectively. The DCV concentration in the effect site was only 11% of plasma concentration after 7 days of treatment. This result was consistent with a previous finding by Ke et al [29] indicating that the active tissue concentration of DCV was 10-fold lower than its plasma concentration.
A significant improvement of the fit to the data was observed for both DCV and ASV when a sigmoid E max model, rather than the E max model, was applied for the exposure and antiviral effect relationship. Given the limited sample size (n =40 for DCV, n=32 for ASV) and unbalanced distribution of population by genotype (n=55 for GT1A, n=17 for GT1B) in the built-in modeling database, it was difficult to estimate the IC 50 of DCV and ASV for both HCV GT1A and GT1B. The dif- Figure 2 . Goodness of fit plots in log-transformed scale (A) and normal scale (B) for the PK models of DCV and ASV. Circles represent observed concentrations. Solid and dashed lines are lowest regression lines and unity lines, respectively. The size of the symbol is proportional to the precision; a larger symbol indicates a more precise (i.e., based on a larger sample size) observation.
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Acta Pharmacologica Sinica ferences in fold for the IC 50 for GT1B vs GT1A were fixed to the values (0.18 for DCV and 0.3 for ASV) reported in previous preclinical studies [13, 51] . The IC 50 of DCV was estimated to be 0.041 μg/L (55.5 pmol/L, RSE 50.3%) and 0.0074 μg/L (10.0 pmol/L) for GT1A and GT1B replicons, respectively, thus indicating that DCV has significant potency against both the GT1A and GT1B HCV replicons. This result confirmed a previous estimate of IC 50 toward the GT1 replicons (50 pmol/L against GT1A, 9 pmol/L against GT1B) [51] . In in vitro studies, ASV demonstrated significant antiviral activity in the HCV replicon cell systems representing GT1A and GT1B, with IC 50 values of 4.0 and 1.2 nmol/L, respectively [13] . The IC 50 of ASV in our model was estimated to be similar: 2.45 μg/L (3.2 nmol/L, RSE 96.4%) and 0.74 μg/L (0.98 nmol/L) for GT1A and GT1B replicons, respectively. The coefficients of the exponential function describing the IC 50 of DCV changing over time for GT1A and GT1B replicons were estimated to be 0.43 and 0.13, respectively. This result revealed that the IC 50 of DCV would increase up to 423-and 6.2-fold for GT1A and GT1B replicons after 2 weeks of DCV monotherapy, thus potentially accounting for the viral rebound experienced in most patients on or before day 7 of treatment. Because no obvious resistance-associated viral rebound emerged in ASV SAD and MAD studies, the IC 50 of ASV for both GT1A and GT1B replicons would only increase 3.1-fold, even with 24 weeks of ASV monotherapy treatment, according to our prediction. The large inter-individual variability of parameter estimates might be due to the lack of individual-level plasma concentrations, the inter-study variability of viral load data and the difference in the preexistence of drug-resistant mutants within a patient population.
The goodness-of-fit plots showed no evidence of model misspecification (Figure 4) , and individual prediction plots (supplementary Figures S1-S4) showed that the developed HCV VD model described not only the sustained viral decline and viral breakthrough during treatment but also the viral rebound after therapy.
Model evaluation
The predictive performance of the model was assessed through external validation by comparing the expected and observed virological response rates in 2 Phase IIa studies (AI447011 [43, 44] and AI447017 [45] [46] [47] ), 3 Asian Phase III studies (AI447026 [48] , AI447031 [49] and AI447036 [50] ) and 1 global Phase III study AI447028 [14] . The comparison between the predicted response rates of DCV and ASV combination therapy in patients with GT1A and GT1B HCV and observations in the validation studies are shown in Figure 5 . Because the 100 mg BID of the ASV softgel capsule without regard to meals used in Phase III produced similar exposures relative to 200 mg BID of Phase II tablet [52] , the observed virological response rates of dual treatment with DCV 60 mg QD and ASV 200 mg BID tablet or 100 mg BID softgel capsule in patients with GT1B HCV infection were pooled and evaluated in the same simulated scenario, as shown in Figure 5 , panel 1. In general, the observed response rates from treatment-naïve patients, null responders or patients intolerant/ineligible to PR therapy fell within the 95% confidence intervals of the median. The simulation scenario of dual treatment of DCV 60 mg QD+ASV 200 mg QD in HCV GT1B patients intolerant to, or medically ineligible for, PR therapy is shown in Figure 5 , panel 2. Although the observed complete early virological response (EVR) rate at week 12 and the end-of-treatment response (ETR) rate at week Figure 3A . Estimated vs observed DCV (A) PK profiles after single-dose (left panels) and multiple-dose (right panels, steady state) administration in healthy subjects, HCV patients and hepatic impairment subjects. Each symbol represents the observed mean plasma concentration at each time point in an arm of a trial and is symbol-coded by dose level. The size of the symbol is proportional to the precision; a larger symbol indicates a more precise (ie, based on a larger sample size) observation. The lines are the predicted PK time profiles based on developed PK models.
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Acta Pharmacologica Sinica Figure 3B . Estimated vs observed ASV PK profiles after single-dose (left panels) and multiple-dose (right panels, steady state) administration in healthy subjects, HCV patients and hepatic impairment subjects. Each symbol represents the observed mean plasma concentration at each time point in an arm of a trial and is symbol-coded by dose level. The size of the symbol is proportional to the precision; a larger symbol indicates a more precise (ie, based on a larger sample size) observation. The lines are the predicted PK time profiles based on developed PK models.
24 were lower than the predictions, the model provided a good prediction of the rapid virologic response (RVR) rates at week 4 and SVR rates 4, 12 and 24 weeks after the end of the 24-week treatment. In HCV GT1A patients intolerant to, or medically ineligible for, PR therapy in the AI447011 sentinel cohort treated with DCV 60 mg QD+ASV 600 mg BID for 24 weeks, the observed response rates were below the 95% confidence interval therapy ( Figure 5, panel 3 ). This result is most probably due to the small sample size (n=11) in the AI447011 sentinel cohort and to our model having been developed with viral load data derived mostly from treatment-naïve patients (approximately 80%).
Discussion
In this article, we propose a PK/VD model to quantify changes in viral load with respect to changing DCV or ASV concentra- tions in patients with GT1 HCV. This study demonstrates a suitable strategy to predict the clinical endpoints of DCV and ASV combination therapy with early phase PK and viral load data.
To our knowledge, no previous publications have described a PK/VD model for ASV. Guedj et al [21] has presented a multiscale model of HCV viral dynamics for DCV that can predict the extremely rapid decline of HCV RNA, which decreases approximately 2 logs within 6 h post-dose and is followed by a slower phase of decline. However, this multiscale model was not able to describe the viral breakthrough or viral rebound associated with persistence of DCV-resistant HCV variants observed in a MAD study [53] . To interpret the rapid emergence of drug-resistant HCV variants in patients treated with telaprevir, another NS3/4A protease inhibitor, Rong et al [25] have developed a VD model with five variables: target cells, drugsensitive virus, drug-resistant virus, cells infected with drugsensitive virus, and cells infected with resistant virus. Cells infected with drug-sensitive virus were assumed to generate drug-resistant virus with low probability. The preexistence and generation of drug-resistant mutants during therapy, which were less sensitive to the drug, resulted in viral rebound and relapse. We attempted to use Rong's model to fit our data but found that this model was too complicated to converge and too time consuming in NONMEM. Therefore, a simple generalized VD model with three variables and an increasing IC 50,ijk changing over time during therapy was chosen for our analysis.
According to theory [54] , the first phase of decline is due to treatment effectiveness in blocking viral production, E, and results in a decline in viral load at a rate near the virion clearance rate, c, with the magnitude of viral decline dependent on E. With lower amounts of virus, less de novo infection occurs, and the infected cells are not efficiently replaced, thereby generating a second phase of viral decline at a rate determined mainly by the loss rate of infected cells, δ. Thus, c and δ were the most important and sensitive parameters to capture a biphasic decline in viral load. However, only the first rapid decline phase during the first 24 h has been observed in the monotherapy studies (supplementary Figure S1 and Figure  S3 ). After that, the viral load rebounds to the baseline level, which is mainly determined by the virion production rate p. Therefore, c and p were re-estimated for best fitting to the data, and the rest of the system-specific parameters in this VD model were fixed to the literature values. Dahari et al [55] have extended this generalized model through the inclusion of homeostatic proliferation of both uninfected and infected cells, to explain the "shoulder phase" (4-28 days) of a triphasic decline in which the viral load decays slowly or remains constant. Nevertheless, such triphasic declines have been reported only in patients treated with IFN or IFN plus RBV [56] ; moreover, these declines were not observed in our study and do not occur frequently in common clinical practice [57] . Furthermore, Rong et al [25] have found that the proliferation of infected hepatocytes is negligible in fitting the data of another protease inhibitor, telaprevir. A sensitivity analysis of the inclusion of proliferation rates for neither, one or both uninfected and infected hepatocytes in our model was conducted. The results showed that removing the proliferation rate for both uninfected and infected cells did not result in significant changes in OFV and model performance. For simplicity, proliferation rates for hepatocytes were excluded in our VD model. The prediction of later-phase virological response rate from early phase outcomes is a critical and challenging issue for the development of HCV antiviral agents. RVR [58, 59] and EVR [60] are considered useful and important predictors of SVR across genotypes in patients with chronic HCV infection. However, these methods are often relatively rough and inaccurate. Many studies [15, [23] [24] [25] [26] have revealed that PK/VD modeling analysis is a better, more accurate approach to predict virological response from viral load data. A common drawback of most these previous studies is that their models do not exhibit the prediction capability of virological response beyond the time range of the viral load observations. The simulation of three scenarios with different dosing regimens and populations showed that our approach provides the possibility to extrapolate predictions of external response rates during therapy and SVR rates post-treatment for HCV GT1B null responders only, by using PK and viral load data from studies no longer than 2 weeks in duration.
In the current era of anti-HCV drug therapy, combining multiple DAAs from different classes is a primary approach for improving antiviral effects, decreasing the doses of individual drugs, limiting the side effects of antiviral drugs and preventing the emergence of drug-resistant viruses [16] . Mathematical models of viral infection dynamics provide an ideal tool for optimizing the benefits of multi-drug combinations via the investigation of interactions between the combined drugs. Biological research exploring the mechanism of drug combination effects indicates that the relationship between two DAAs targeting different viral proteins is intermediate between additive and synergistic [61] . Thus, a simulation was also performed by assuming that the combined efficacy of DCV and ASV was based on the Bliss independence theory [16] . However, overpredictions were observed in all simulated scenarios. Ideally, intensive viral load data from a DCV and ASV combination therapy study could be used to investigate the potential pharmacodynamic interactions between DCV and ASV, which might improve prediction of response rates to combination therapy. Unfortunately, the currently available individuallevel viral load data obtained from AI447011 and AI447017 were too sparse to estimate the synergistic factor between DCV and ASV.
In conclusion, the integrated PK/VD model developed in this study is the first effort to explain the complex relationships among PK exposure, short-term viral load changes and longterm virological response in HCV GT1 infected patients receiving monotherapy or combination therapy with DCV and ASV. This modeling and simulation approach may provide a useful tool for the preliminary evaluation of later-phase long-term antiviral effects of treatments with a combination of direct acting antiviral agents with different mechanisms of action in HCV patients, on the basis of the information in the PK profile and the effect on viral load changes for each antiviral agent at an early development stage.
